- Home
- ARTV vs ARMP Comparison
ARTV vs ARMP Comparison
Compare ARTV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- ARMP
- Stock Information
- Founded
- ARTV 2019
- ARMP N/A
- Country
- ARTV United States
- ARMP United States
- Employees
- ARTV N/A
- ARMP N/A
- Industry
- ARTV
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARTV
- ARMP Health Care
- Exchange
- ARTV NYSE
- ARMP Nasdaq
- Market Cap
- ARTV 61.9M
- ARMP 52.1M
- IPO Year
- ARTV 2024
- ARMP N/A
- Fundamental
- Price
- ARTV $2.24
- ARMP $1.23
- Analyst Decision
- ARTV Strong Buy
- ARMP Strong Buy
- Analyst Count
- ARTV 7
- ARMP 1
- Target Price
- ARTV $20.00
- ARMP $7.00
- AVG Volume (30 Days)
- ARTV 679.3K
- ARMP 30.3K
- Earning Date
- ARTV 05-22-2025
- ARMP 05-06-2025
- Dividend Yield
- ARTV N/A
- ARMP N/A
- EPS Growth
- ARTV N/A
- ARMP N/A
- EPS
- ARTV N/A
- ARMP N/A
- Revenue
- ARTV $251,000.00
- ARMP $5,174,000.00
- Revenue This Year
- ARTV N/A
- ARMP $8.43
- Revenue Next Year
- ARTV N/A
- ARMP N/A
- P/E Ratio
- ARTV N/A
- ARMP N/A
- Revenue Growth
- ARTV N/A
- ARMP 14.24
- 52 Week Low
- ARTV $1.78
- ARMP $0.90
- 52 Week High
- ARTV $17.31
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- ARMP 39.22
- Support Level
- ARTV N/A
- ARMP $1.11
- Resistance Level
- ARTV N/A
- ARMP $1.30
- Average True Range (ATR)
- ARTV 0.00
- ARMP 0.14
- MACD
- ARTV 0.00
- ARMP 0.01
- Stochastic Oscillator
- ARTV 0.00
- ARMP 42.86
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.